Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P[R]EBEN study in relapsed aggressive non-Hodgkin lymphoma
NL-OMON49078Phase 2Completed
- Sponsor
- Aarhus University Hospital
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pixantrone, etoposide, bendamustine and rituximab in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Aarhus University Hospital. Primary endpoints: Objective response rate and Progression-free survival. Started Nov 2018; status: completed.
02
Drugs
pixantroneetoposidebendamustinerituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON49078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49078.